Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal — Stella

Home/Opiate Withdrawal Syndrome/Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

View on ClinicalTrials.gov

Recruiting

Back to Opiate Withdrawal Syndrome trials

Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Mountain Manor Treatment Center, Baltimore, Maryland

University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

University of Pennsylvania

Enrollment target

~150 participants

Started

January 2024

Primary completion

August 2026

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.